China’s domestically developed CAR-T therapy, Carteyva, is giving new hope to patients with relapsed/refractory lymphoma. From a personalized treatment process to promising survival data, this breakthrough cell therapy is reshaping the future of cancer care in China.
Discover how CARTEYVA, a CD19-directed CAR-T therapy is advancing treatment for follicular lymphoma with promising results and local availability in China.
Carteyva, a CAR T-cell therapy developed based on cell processing platform of Breyanzi, is not approved for treatment of r/r follicular lymphoma.
CAR T-cell therapy is a personalized treatment. Feel free to contact us, find out whether CAR T-cell therapy is the right treatment for you or your loved one.
Whether you’re a patient, caregiver, or medical professional, our team can connect you with leading CAR-T treatment centers and clinical experts in China.
Fill out the form below and we’ll get back to you shortly with personalized support.